Management of Antineoplastic Extravasation: ONS-ASCO Guideline

Management of Antineoplastic Extravasation: O...

Up next

Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update

Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on ...  Show more

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resist ...  Show more

Recommended Episodes

Key Abstracts in GU Cancers at ASCO24
ASCO Daily News

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting.

<span style= "text-decoration: underline;">TRANSCRIPT</span>

  Show more

GU Oncology Highlights From ASCO24
ASCO Daily News

<span class= "normaltextrun"><span style= "font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-ansi-language: EN-US; mso-f ...

  Show more

ADCs in Breast Cancer: Sequencing, Resistance, and Managing Toxicity
ASCO Daily News

<span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. Hope Rugo and Sara Tolaney discuss the promise of antibody-drug conjugates (ADCs) in the treatment of breast cancer, highlighting key trials that shed light on matching the right ADC to the right p ...

  Show more

Treatment De-escalation for Favorable Risk Breast Cancer
JCO Oncology Practice Podcast

Dr. Chino talks with Dr. Atif Khan and Dr. Lola Fayanju about the shift in breast cancer management from reducing locoregional recurrence and improving breast cancer mortality to deintensification, shared decision making, and improved quality of life. This discussion will be base ...  Show more